ID   ERO1B_HUMAN             Reviewed;         467 AA.
AC   Q86YB8; B4DF57; Q5T1H4; Q8IZ11; Q9NR62;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   28-JAN-2026, entry version 178.
DE   RecName: Full=ERO1-like protein beta {ECO:0000303|PubMed:10818100};
DE            Short=ERO1-L-beta {ECO:0000303|PubMed:10818100};
DE            EC=1.8.3.2 {ECO:0000269|PubMed:11707400, ECO:0000269|PubMed:21091435};
DE   AltName: Full=Endoplasmic reticulum oxidoreductase beta {ECO:0000312|HGNC:HGNC:14355};
DE   AltName: Full=Endoplasmic reticulum oxidoreductin-1-like protein B;
DE   AltName: Full=Oxidoreductin-1-L-beta;
DE   Flags: Precursor;
GN   Name=ERO1B {ECO:0000312|HGNC:HGNC:14355}; Synonyms=ERO1LB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, GLYCOSYLATION, INDUCTION, AND VARIANT GLN-465.
RX   PubMed=10818100; DOI=10.1074/jbc.m003061200;
RA   Pagani M., Fabbri M., Benedetti C., Fassio A., Pilati S., Bulleid N.J.,
RA   Cabibbo A., Sitia R.;
RT   "Endoplasmic reticulum oxidoreductin 1-lbeta (ERO1-Lbeta), a human gene
RT   induced in the course of the unfolded protein response.";
RL   J. Biol. Chem. 275:23685-23692(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-129.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, POSSIBLE HOMODIMERIZATION, AND ASSOCIATION
RP   WITH P4HB.
RX   PubMed=11707400; DOI=10.1093/emboj/20.22.6288;
RA   Mezghrani A., Fassio A., Benham A., Simmen T., Braakman I., Sitia R.;
RT   "Manipulation of oxidative protein folding and PDI redox state in mammalian
RT   cells.";
RL   EMBO J. 20:6288-6296(2001).
RN   [6]
RP   INTERACTION WITH ERP44.
RX   PubMed=11847130; DOI=10.1093/emboj/21.4.835;
RA   Anelli T., Alessio M., Mezghrani A., Simmen T., Talamo F., Bachi A.,
RA   Sitia R.;
RT   "ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin
RT   family.";
RL   EMBO J. 21:835-844(2002).
RN   [7]
RP   INDUCTION.
RX   PubMed=12752442; DOI=10.1046/j.1432-1033.2003.03590.x;
RA   Gess B., Hofbauer K.H., Wenger R.H., Lohaus C., Meyer H.E., Kurtz A.;
RT   "The cellular oxygen tension regulates expression of the endoplasmic
RT   oxidoreductase ERO1-Lalpha.";
RL   Eur. J. Biochem. 270:2228-2235(2003).
RN   [8]
RP   ACTIVITY REGULATION.
RX   PubMed=15161913; DOI=10.1074/jbc.m404992200;
RA   Nerini Molteni S., Fassio A., Ciriolo M.R., Filomeni G., Pasqualetto E.,
RA   Fagioli C., Sitia R.;
RT   "Glutathione limits Ero1-dependent oxidation in the endoplasmic
RT   reticulum.";
RL   J. Biol. Chem. 279:32667-32673(2004).
RN   [9]
RP   INTERACTION WITH ERO1L AND P4HB, HOMODIMERIZATION, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF CYS-390; CYS-393 AND CYS-396.
RX   PubMed=16012172; DOI=10.1074/jbc.m505023200;
RA   Dias-Gunasekara S., Gubbens J., van Lith M., Dunne C., Williams J.A.,
RA   Kataky R., Scoones D., Lapthorn A., Bulleid N.J., Benham A.M.;
RT   "Tissue-specific expression and dimerization of the endoplasmic reticulum
RT   oxidoreductase Ero1beta.";
RL   J. Biol. Chem. 280:33066-33075(2005).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-140.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.m500324-mcp200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, HOMODIMERIZATION, DISULFIDE BONDS,
RP   AND MUTAGENESIS OF CYS-90; CYS-95; CYS-100; CYS-130; CYS-393 AND CYS-396.
RX   PubMed=21091435; DOI=10.1042/bj20101357;
RA   Wang L., Zhu L., Wang C.C.;
RT   "The endoplasmic reticulum sulfhydryl oxidase Ero1beta drives efficient
RT   oxidative protein folding with loose regulation.";
RL   Biochem. J. 434:113-121(2011).
CC   -!- FUNCTION: Oxidoreductase involved in disulfide bond formation in the
CC       endoplasmic reticulum. Efficiently reoxidizes P4HB/PDI, the enzyme
CC       catalyzing protein disulfide formation, in order to allow P4HB to
CC       sustain additional rounds of disulfide formation. Other protein
CC       disulfide isomerase family members can also be reoxidized, but at lower
CC       rates compared to P4HB, including PDIA2 (50% of P4HB reoxidation rate),
CC       as well as PDIA3, PDIA4, PDIA6 and NXNDC12 (<10%). Following P4HB
CC       reoxidation, passes its electrons to molecular oxygen via FAD, leading
CC       to the production of reactive oxygen species (ROS) in the cell. May be
CC       involved in oxidative proinsulin folding in pancreatic cells, hence may
CC       play a role in glucose homeostasis. {ECO:0000269|PubMed:11707400,
CC       ECO:0000269|PubMed:21091435}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 R'C(R)SH + O2 = R'C(R)S-S(R)CR' + H2O2;
CC         Xref=Rhea:RHEA:17357, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:16520, ChEBI:CHEBI:17412; EC=1.8.3.2;
CC         Evidence={ECO:0000269|PubMed:11707400, ECO:0000269|PubMed:21091435};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17358;
CC         Evidence={ECO:0000305|PubMed:11707400, ECO:0000305|PubMed:21091435};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[protein]-dithiol + O2 = [protein]-disulfide + H2O2;
CC         Xref=Rhea:RHEA:59116, Rhea:RHEA-COMP:10593, Rhea:RHEA-COMP:10594,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:16240, ChEBI:CHEBI:29950,
CC         ChEBI:CHEBI:50058; Evidence={ECO:0000269|PubMed:11707400,
CC         ECO:0000269|PubMed:21091435};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:59117;
CC         Evidence={ECO:0000305|PubMed:11707400, ECO:0000305|PubMed:21091435};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:21091435};
CC   -!- ACTIVITY REGULATION: Glutathione may be required to regulate its
CC       activity in the endoplasmic reticulum. {ECO:0000269|PubMed:15161913}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Heterodimer with ERO1A;
CC       disulfide-linked. Also detected as monomer. Homodimers may be somewhat
CC       less active than monomers. Interacts with P4HB. Interacts with ERP44.
CC       {ECO:0000269|PubMed:11847130, ECO:0000269|PubMed:16012172,
CC       ECO:0000269|PubMed:21091435}.
CC   -!- INTERACTION:
CC       Q86YB8; P30101: PDIA3; NbExp=2; IntAct=EBI-2806988, EBI-979862;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10818100}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10818100}; Lumenal side
CC       {ECO:0000269|PubMed:10818100}. Note=The association with ERP44 may be
CC       essential for its retention in the endoplasmic reticulum.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q86YB8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86YB8-2; Sequence=VSP_056988;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the digestive tract, including
CC       the duodenum and lower digestive tract. In the stomach, highly
CC       expressed in enzyme-producing chief cells (at protein level). In the
CC       pancreas, expressed in islets of Langerhans and, at lower levels, in
CC       enzyme-secreting cells (at protein level). Detected at low level in
CC       many other tissues. {ECO:0000269|PubMed:10818100,
CC       ECO:0000269|PubMed:16012172}.
CC   -!- INDUCTION: Up-regulated by inducers of the unfolded protein response
CC       (UPR). {ECO:0000269|PubMed:10818100, ECO:0000269|PubMed:12752442}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10818100,
CC       ECO:0000269|PubMed:16263699}.
CC   -!- PTM: The Cys-90/Cys-95 and Cys-393/Cys-396 disulfide bonds constitute
CC       the redox-active center. The Cys-90/Cys-95 disulfide bond accepts
CC       electron from P4HB and funnel them to the active site disulfide Cys-
CC       393/Cys-396. The Cys-81/Cys-390 disulfide bond may be critical for
CC       structural stability. Two long-range disulfide bonds participate in
CC       loose feedback regulation. The Cys-90/Cys-130 disulfide bond may be the
CC       predominant regulatory switch to modulate the catalytic activity, while
CC       the Cys-100/Cys-262 disulfide bond may play an auxiliary regulatory
CC       role. {ECO:0000305|PubMed:21091435}.
CC   -!- SIMILARITY: Belongs to the EROs family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF252538; AAF97547.1; -; mRNA.
DR   EMBL; AK293941; BAG57318.1; -; mRNA.
DR   EMBL; AL139162; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450309; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032823; AAH32823.2; -; mRNA.
DR   EMBL; BC044573; AAH44573.1; -; mRNA.
DR   CCDS; CCDS31064.1; -. [Q86YB8-1]
DR   RefSeq; NP_063944.3; NM_019891.3. [Q86YB8-1]
DR   AlphaFoldDB; Q86YB8; -.
DR   SMR; Q86YB8; -.
DR   BioGRID; 121155; 58.
DR   FunCoup; Q86YB8; 1790.
DR   IntAct; Q86YB8; 39.
DR   MINT; Q86YB8; -.
DR   STRING; 9606.ENSP00000346635; -.
DR   DrugBank; DB01902; 1-Ethyl-Pyrrolidine-2,5-Dione.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   GlyConnect; 1226; 3 N-Linked glycans (1 site).
DR   GlyCosmos; Q86YB8; 4 sites, 3 glycans.
DR   GlyGen; Q86YB8; 4 sites, 12 N-linked glycans (3 sites).
DR   iPTMnet; Q86YB8; -.
DR   PhosphoSitePlus; Q86YB8; -.
DR   BioMuta; ERO1B; -.
DR   DMDM; 116241353; -.
DR   jPOST; Q86YB8; -.
DR   MassIVE; Q86YB8; -.
DR   PaxDb; 9606-ENSP00000346635; -.
DR   PeptideAtlas; Q86YB8; -.
DR   ProteomicsDB; 4009; -.
DR   ProteomicsDB; 70394; -. [Q86YB8-1]
DR   Pumba; Q86YB8; -.
DR   Antibodypedia; 34698; 190 antibodies from 25 providers.
DR   DNASU; 56605; -.
DR   Ensembl; ENST00000354619.10; ENSP00000346635.5; ENSG00000086619.15. [Q86YB8-1]
DR   GeneID; 56605; -.
DR   KEGG; hsa:56605; -.
DR   MANE-Select; ENST00000354619.10; ENSP00000346635.5; NM_019891.4; NP_063944.3.
DR   UCSC; uc001hxt.4; human. [Q86YB8-1]
DR   AGR; HGNC:14355; -.
DR   ClinPGx; PA134918597; -.
DR   CTD; 56605; -.
DR   DisGeNET; 56605; -.
DR   GeneCards; ERO1B; -.
DR   HGNC; HGNC:14355; ERO1B.
DR   HPA; ENSG00000086619; Tissue enriched (pancreas).
DR   MIM; 615437; gene.
DR   OpenTargets; ENSG00000086619; -.
DR   VEuPathDB; HostDB:ENSG00000086619; -.
DR   eggNOG; KOG2608; Eukaryota.
DR   GeneTree; ENSGT00390000007753; -.
DR   HOGENOM; CLU_023061_2_2_1; -.
DR   InParanoid; Q86YB8; -.
DR   OMA; CYKDRLH; -.
DR   OrthoDB; 269384at2759; -.
DR   PAN-GO; Q86YB8; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q86YB8; -.
DR   BioCyc; MetaCyc:ENSG00000086619-MONOMER; -.
DR   PathwayCommons; Q86YB8; -.
DR   Reactome; R-HSA-264876; Insulin processing.
DR   SignaLink; Q86YB8; -.
DR   SIGNOR; Q86YB8; -.
DR   Agora; ENSG00000086619; -.
DR   BioGRID-ORCS; 56605; 11 hits in 1154 CRISPR screens.
DR   ChiTaRS; ERO1B; human.
DR   GeneWiki; ERO1LB; -.
DR   GenomeRNAi; 56605; -.
DR   Pharos; Q86YB8; Tbio.
DR   PRO; PR:Q86YB8; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q86YB8; protein.
DR   Bgee; ENSG00000086619; Expressed in body of pancreas and 163 other cell types or tissues.
DR   ExpressionAtlas; Q86YB8; baseline and differential.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0071949; F:FAD binding; IEA:InterPro.
DR   GO; GO:0016491; F:oxidoreductase activity; NAS:UniProtKB.
DR   GO; GO:0015035; F:protein-disulfide reductase activity; EXP:Reactome.
DR   GO; GO:0016972; F:thiol oxidase activity; IDA:FlyBase.
DR   GO; GO:0051082; F:unfolded protein binding; NAS:UniProtKB.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:Ensembl.
DR   GO; GO:0006888; P:endoplasmic reticulum to Golgi vesicle-mediated transport; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0030070; P:insulin processing; TAS:Reactome.
DR   GO; GO:0006457; P:protein folding; TAS:UniProtKB.
DR   GO; GO:0034975; P:protein folding in endoplasmic reticulum; IDA:FlyBase.
DR   InterPro; IPR007266; Ero1.
DR   InterPro; IPR037192; ERO1-like_sf.
DR   PANTHER; PTHR12613:SF2; ERO1-LIKE PROTEIN BETA; 1.
DR   PANTHER; PTHR12613; ERO1-RELATED; 1.
DR   Pfam; PF04137; ERO1; 1.
DR   PIRSF; PIRSF017205; ERO1; 1.
DR   SUPFAM; SSF110019; ERO1-like; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Disulfide bond; Electron transport;
KW   Endoplasmic reticulum; FAD; Flavoprotein; Glycoprotein; Membrane;
KW   Oxidoreductase; Proteomics identification; Redox-active center;
KW   Reference proteome; Signal; Transport.
FT   SIGNAL          1..33
FT                   /evidence="ECO:0000255"
FT   CHAIN           34..467
FT                   /note="ERO1-like protein beta"
FT                   /id="PRO_0000008418"
FT   BINDING         186
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q96HE7"
FT   BINDING         188
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q96HE7"
FT   BINDING         199
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q96HE7"
FT   BINDING         251
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q96HE7"
FT   BINDING         254
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q96HE7"
FT   BINDING         286
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q96HE7"
FT   BINDING         299
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q96HE7"
FT   CARBOHYD        122
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        140
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16263699"
FT   CARBOHYD        145
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        383
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        81..390
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   DISULFID        90..130
FT                   /note="Alternate"
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   DISULFID        90..95
FT                   /note="Redox-active; alternate"
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   DISULFID        100..262
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   DISULFID        207..240
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   DISULFID        393..396
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   VAR_SEQ         144..466
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056988"
FT   VARIANT         129
FT                   /note="D -> V (in dbSNP:rs2477599)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028012"
FT   VARIANT         465
FT                   /note="H -> Q (in dbSNP:rs1055851)"
FT                   /evidence="ECO:0000269|PubMed:10818100"
FT                   /id="VAR_019492"
FT   MUTAGEN         90
FT                   /note="C->A: No effect on thiol oxidase activity when DTT
FT                   is used as an electron donor; when associated with A-95.
FT                   Loss of thiol oxidase activity when P4HB is used as an
FT                   electron donor; when associated with A-95."
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   MUTAGEN         95
FT                   /note="C->A: No effect on thiol oxidase activity when DTT
FT                   is used as an electron donor; when associated with A-90.
FT                   Loss of thiol oxidase activity when P4HB is used as an
FT                   electron donor; when associated with A-90."
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   MUTAGEN         100
FT                   /note="C->A: Slightly decreased thiol oxidase activity.
FT                   Significant increased thiol oxidase activity; when
FT                   associated with A-130."
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   MUTAGEN         130
FT                   /note="C->A: Small increase in thiol oxidase activity.
FT                   Significant increased thiol oxidase activity; when
FT                   associated with A-130."
FT                   /evidence="ECO:0000269|PubMed:21091435"
FT   MUTAGEN         390
FT                   /note="C->A: Strong decrease in P4HB-binding. Efficient
FT                   homodimerization with both wild-type and A-390 mutated
FT                   protein."
FT                   /evidence="ECO:0000269|PubMed:16012172"
FT   MUTAGEN         393
FT                   /note="C->A: Some decrease in P4HB-binding. Efficient
FT                   homodimerization with wild-type protein. Loss of thiol
FT                   oxidase activity when DTT or P4HB are used as an electron
FT                   donor; when associated with A-396."
FT                   /evidence="ECO:0000269|PubMed:16012172,
FT                   ECO:0000269|PubMed:21091435"
FT   MUTAGEN         396
FT                   /note="C->A: Some decrease in P4HB-binding. Efficient
FT                   homodimerization with wild-type protein, but loss of
FT                   homodimerization with A-396 mutated protein. Loss of thiol
FT                   oxidase activity when DTT or P4HB are used as an electron
FT                   donor; when associated with A-393."
FT                   /evidence="ECO:0000269|PubMed:16012172,
FT                   ECO:0000269|PubMed:21091435"
SQ   SEQUENCE   467 AA;  53543 MW;  4DA8753DDEE15314 CRC64;
     MSQGVRRAGA GQGVAAAVQL LVTLSFLRSV VEAQVTGVLD DCLCDIDSID NFNTYKIFPK
     IKKLQERDYF RYYKVNLKRP CPFWAEDGHC SIKDCHVEPC PESKIPVGIK AGHSNKYLKM
     ANNTKELEDC EQANKLGAIN STLSNQSKEA FIDWARYDDS RDHFCELDDE RSPAAQYVDL
     LLNPERYTGY KGTSAWRVWN SIYEENCFKP RSVYRPLNPL APSRGEDDGE SFYTWLEGLC
     LEKRVFYKLI SGLHASINLH LCANYLLEET WGKPSWGPNI KEFKHRFDPV ETKGEGPRRL
     KNLYFLYLIE LRALSKVAPY FERSIVDLYT GNAEEDADTK TLLLNIFQDT KSFPMHFDEK
     SMFAGDKKGA KSLKEEFRLH FKNISRIMDC VGCDKCRLWG KLQTQGLGTA LKILFSEKEI
     QKLPENSPSK GFQLTRQEIV ALLNAFGRLS TSIRDLQNFK VLLQHSR
//
